Quality of Life, Upper Extremity Function and the Effect of Lymphedema Treatment in Breast Cancer Related Lymphedema Patients by Park, Ji Eung et al.
Quality of Life, Upper Extremity Function and 
the Eff  ect of Lymphedema Treatment in Breast 
Cancer Related Lymphedema Patients
Ji Eung Park, M.D., Hye Jin Jang, M.D., Kwan Sik Seo, M.D., Ph.D.
Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
Objective  To evaluate quality of life (QOL), upper extremity function and the eff  ect of lymphedema treatment in 
patients with breast cancer related lymphedema.
Method  Th   e basic data comprised medical records (detailing age, sex, dominant side, location of tumor, cancer 
stage, operation record, cancer treatment and limb circumferences) and questionnaires (lymphedema duration, 
satisfaction, self-massage). Further to this, we measured upper extremity function and QOL, administered the 
DASH (Disabilities of Arm Shoulder and Hand outcome measure) and used the EORTC (European Organization 
for Research and Treatment of Cancer)-QLQ-C30 and the EORTC-QLQ-Br23. Results of these were calculated as 
main outcome variables.
Results  The questionnaire responses and arm circumferences of 59 patients with breast cancer related 
lymphedema were analyzed. In the DASH questionnaire, it was found that the older the lymphedema patient 
was, the lower their upper extremity function. On the EORTC-QLQ, patients with metastasis had significantly 
lower scores in physical functioning and role functioning. In terms of upper extremity circumference, there was a 
signifi  cant upper extremity size reduction after lymphedema treatment.
Conclusion  Th   ere were several dissociations between some subscales of quality of life questionnaires and those 
of upper extremity functions. Upper extremity function was correlated with the age of breast cancer patients and 
QOL was infl  uenced by M-stage. Lymphedema treatment was found to be eff  ective in reducing edema in patients 
with breast cancer related lymphedema.
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INTRODUCTION
Upper extremity lymphedema is a chronic complication 
that appears frequently after breast cancer treatment. It 
is not only a disease that causes cosmetic problems, but 
also one that exerts eff  ects on psychosocial adjustment, 
quality of life and functional status. In part related to 
growing obesity levels, a westernization of diet habits and 
a decrease in breast feeding, the incidence of breast can-
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cer is the highest of all female cancers.
Given this, interest in lymphedema has developed con-
current to a rise in breast cancer treatment. In its initial 
period, the disease involves a swollen sensation or mild 
discomfort in the upper extremities, and as it progresses, 
symptoms such as a limitation of joint motion, pain, and 
skin discoloration develop and the risk of infection in-
creases.
Lymphedema is a factor that mediates significant ef-
fects on the function of upper extremities as well as qual-
ity of life after breast cancer surgery. Th  us  lymphedema 
treatments, quality of life and upper extremity function 
after treatment have been frequently studied.
Among the current treatments for lymphedema, com-
plex decongestive physical therapy (CDT) is the most 
common. CDT includes education on skin care to prevent 
infection, manual lymphatic drainage that accelerates the 
drainage of excess lymph fl  uids, non-elastic bandaging to 
maintain the decreased edema by elevating tissue pres-
sure, and special exercise therapy to accelerate the drain-
age of lymph fl  uid by muscle contraction and to enhance 
the range of joint motion.
1 The method that has been 
applied most widely to assess treatment outcomes is to 
measure the circumference reduction in certain areas of 
the aff  ected arm. Additional methods include evaluating 
the reduction of the aff  ected arm’s volume by immersing 
it in water and then measuring the volume of overfl  owed 
water, and measuring the tension in the aff  ected tissue.
Studies on quality of life and upper extremity func-
tion after breast cancer treatment have been frequently 
conducted, and it has been reported that quality of life 
in lymphedema patients is lower than in those patients 
without the condition.
2 However, studies that consider 
both quality of life and upper extremity function within 
a patient group that has received treatment for lymph-
edema are rare.
In this study, the capacity of lymphedema therapies 
to reduce lymphedema was assessed, alongside survey 
results on quality of life and upper extremity function ac-
cording to the demographic information of lymphedema 
patients. This will allow us to apply this information as 
a clinical index for treatment outcomes of lymphedema 
that had developed after breast cancer surgery, measur-
ing both quality of life and upper extremity function.
MATERIALS AND METHODS
Subjects
134 patients were treated with CDT for breast cancer 
related lymphedema from January 2007 to March 2010 at 
department of rehabilitation medicine, Seoul National 
University Hospital in Seoul, South Korea. Of these, 64 
patients visited the rehabilitation outpatient clinic from 
11th May 2010 to 14th June 2010. After agreement, 59 
patients responded to the survey and fi  lled out the ques-
tionnaires independently.
Methods
Questionnaire: To evaluate quality of life after lymph-
edema treatment, a questionnaire survey was conducted 
applying the European Organization for Research and 
Treatment of Cancer (EORTC)-QLQ-C30 and the EORTC-
QLQ-Br23, which were designed for breast cancer pa-
tients. For the evaluation of upper extremity function, 
the short version of the Disabilities of Arm Shoulder and 
Hand outcome measure (DASH) was applied. Th  e  onset 
of the development of lymphedema, the dominant arm, 
and patients’ satisfaction level with their breast cancer 
and lymphedema treatments, as well as whether or not 
self-massage was being performed at home were as-
sessed by a questionnaire that was designed for this study 
(Appendix 1).
In the EORTC-QLQ-C30, there are subcategories of 
global health status, function scale and symptom scale. 
Physical functioning, role functioning, emotional func-
tioning, cognitive functioning, social functioning are as-
sessed in the function scale, whereas fatigue, nausea and 
vomiting, pain, dyspnea, insomnia, appetite loss, consti-
pation, diarrhea, and fi  nancial diffi   culty are assessed in 
the symptom scale. The EORTC-QLQ-Br23 also consists 
of function scale and symptom scale. Body image, sexual 
functioning, sexual enjoyment and future perspective 
are assessed in the function scale, whereas systematic 
therapy side effects, breast symptoms, arm symptoms 
and emotional response to hair loss are assessed in the 
symptom scale.
Medical history: Medical records were reviewed be-
tween April 2010 and May 2010, similar to the period in 
which we acquired questionnaire responses. Th  is  allowed 
us to obtain the information about those subjects who 
responded to the questionnaire, i.e., their age, gender, Ji Eung Park, et al.
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whether or not their lesion was in the dominant arm, 
cancer stage, surgical records and whether or not che-
motherapy, radiotherapy or hormone therapy had been 
performed. Based on this data, alongside results from 
the EORTC-QLQ-C30, the EORTC-QLQ-Br23, and the K-
DASH, the demographic characteristic of subjects as well 
as the factors related with breast cancer were evaluated 
to assess the associations between quality of life and up-
per extremity function.
To assess improvements in lymphedema after treat-
ment, measurement of the circumference of the upper 
arm was carried out. At the metacarpophalangeal joints, 
the wrist, 10 cm below the elbow, at the elbow, and 10 
cm above the elbow level, the circumference was mea-
sured horizontally by rulers. Records of circumference 
measurement prior to and after lymphedema treatments 
performed both at outpatient clinics and in the physi-
cal therapy room were used. Lymphedema treatment for 
each patient comprised two weeks of complex decon-
gestive physical therapy (CDT). Th   ey received skin care, 
manual lymphatic drainage, compression bandaging, 
and undertook an exercise regime for 30 minutes a day, 
fi  ve days a week.
Statistical analysis: For statistical analysis, SPSS 18.0 
was used. To analyze whether the demographic charac-
teristics and the factors pertinent to breast cancer were 
related with questionnaire results measuring quality of 
life and upper extremity function, multiple regression 
analysis, Kruskal Wallis Test and Mann-Whitney U test 
were applied. To assess the eff  ect of lymphedema treat-
ment, the circumference of arm data were analyzed by 
Paired Samples t-Tests.
Written informed consent was obtained prior to the 
study from all subjects. The study was performed in ac-
cordance with the principles set forth in the Declaration 
of Helsinki.
RESULTS
Patient demographic characteristics and breast cancer 
treatment
Out of the 134 patients who received CDT for breast 
cancer related lymphedema from January 2007 to March 
2010 and the 64 patients who visited the rehabilitation 
outpatient clinic between 11th May 2010 and 14th June 
2010, 59 patients filled out the EORTC-QLQ-C30, the 
EORTC-QLQ-Br23 and the K-DASH questionnaire. Th  ere 
were seven patients with shoulder pain and axillary web 
syndrome, which can aff  ect upper extremity functions. In 
terms of average age, 14 patients were in their 40s (23.7%), 
23 in their 50s (39.0%), and 22 patients were in their 60s 
or above (37.3%). The mean age was 56.31±9.49 years. 
Th   e average duration of lymphedema was 4.21±2.11 years 
(Table 1). Concerning breast cancer treatments, all pa-
tients had undergone surgical treatment, with radiation 
therapy being given to 47 patients (79.7%), chemotherapy 
to 53 patients (89.8%), and hormonal therapy to 33 pa-
tients (55.9 %) (Table 2).
Table 1. Patient Demographics 
N%
Total 59 100
Age
40-49 14   23.7
50-59 23   39.0
60- 22   37.3
Dominant side 28   50.0
Unknown   3     5.1
Cancer stage
T
pT1   8   13.6
pT2 32   52.4
pT3   9   15.3
pT4   3     5.1
Unknown   7   11.9
N
N0 11   18.6
N1 16   27.1
N2 14   23.7
N3 11   18.6
Unknown   7   11.9
M
M0 42   71.2
M1 11   18.6
Unknown   6   10.2
Stage
I   4     6.8
II 17   28.8
III 21   35.6
IV 11   18.6
Unknown   6   10.2QOL, Function and Treatment of BCRL Patients
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Upper extremity function & quality of life
Upper extremity function in breast cancer related 
lymphedema: DASH questionnaire results were ana-
lyzed, considering patients’ age, the lesion side of breast 
cancer, the disease stage of breast cancer, whether or not 
axillary lymph node dissection was performed during 
surgery, whether or not chemotherapy, radiation therapy 
or hormone therapy had been performed, the duration 
of lymphedema, the satisfaction level with treatments, 
and whether or not self-massage was being performed at 
home.
Considering the correlation between age and K-DASH 
scores, it was found that the older the patient was, the 
lower their upper limb function (Regression coeffi   cient: 
-0.834, p-value: 0.012), but the duration of lymphedema 
and postoperation period were not significantly cor-
related with age. In addition, no signifi  cant relation was 
found between upper extremity function and lesion side, 
axillary lymph node dissection having been performed, a 
history of chemotherapy, radiation therapy or self-mas-
sage, and treatment satisfaction level. Th   ere was also no 
signifi  cant diff  erence in K-DASH scores between patients 
with shoulder pain and those without (p-value: 0.263).
Quality of life in breast cancer related lymphedema 
patients: The EORTC questionnaire was used to mea-
sure this. As with the survey of upper extremity function, 
based on the general demographic characteristic of pa-
tients and the factors associated with breast cancer, qual-
ity of life results were analyzed.
In EORTC-QLQ-C30, the global health status of metat-
static cancer patients was lower than that of non-meta-
static patients. Physical functioning and role functioning 
were also similarly correlated with metastatic breast can-
cer patients. Emotional functioning, cognitive function-
ing and social functioning were, however, not correlated 
with any demographic factors, breast cancer factors or 
treatments factors. Other symptom scales, including pain 
and appetite loss showed some correlations (Table 3).
In EORTC- QLQ-Br23, sexual functioning, sexual en-
joyment were negatively correlated with age. Future 
perspective was lower in patients who had undergone 
hormone therapy. Body image, systemic therapy side ef-
fects, breast symptoms, arm symptoms and response to 
hair loss were not correlated with any demographic fac-
tors, breast cancer factors or treatment factors (Table 4). 
Additionally, there was no signifi  cant relationship found 
between shoulder pain and quality of life in the EORTC-
QLQ-C30 or the EORTC-QLQ-Br23 results, except for the 
pain item (p-value: 0.0014).
Upper extremity function & quality of life: For the 
upper extremity function questionnaire, the K-DASH, 
there were significant correlations with patient age. For 
the two QOL questionnaires, there were also significant 
correlations with the presence of metastasis, and some 
with age, particularly related to sexual functioning. No 
other factors investigated in this study were signifi  cantly 
correlated with questionnaire results (the lesion side of 
breast cancer, the disease stage of breast cancer, whether 
or not axillary lymph node dissection was performed 
during surgery, whether or not chemotherapy, radiation 
therapy or hormone therapy, treatment satisfaction level, 
and whether or not self-massage was being performed at 
home).
Eﬀ  ectiveness of lymphedema treatments
After two weeks of CDT treatment, pre-treatment and 
post-treatment patient arm circumferences were com-
pared. Paired sample t-tests were performed and the 
results showed that circumference at every level, i.e. the 
circumference at the wrist level, at 10 cm below the el-
bow, at the elbow, and 10 cm above the elbow level, was 
signifi  cantly reduced after l treatment (Table 5).
Table 2. Breast Cancer Treatments of Participants
N%
Cancer treatment
Surgery 59 100.0
Radiotherapy 47 79.7
Chemotherapy 53 89.8
Hormone therapy 33 55.9
Operation
MRM 37 62.7
Quadrantectomy 18 30.5
Unknown   4 6.8
ALND 31 52.5
Unknown   3 5.1
Self massage 42 71.2
MRM: Modified radical mastectomy, ALND: Axillary 
lymph node dissectionJi Eung Park, et al.
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DISCUSSION
Th   e lymphatic system is the system that collects lymph 
fluid from the skin, subcutaneous tissues, muscles, 
bones and other tissues and circulates it to blood vessels. 
Lymph fl  uid consists of water, proteins and cell debris. As 
lymph fl  uid within lymph ducts circulates to blood ves-
sels, the body maintains optimal conditions. However, in 
patients with breast cancer, the lymphatic system active 
in the breast area is destroyed by surgery or other treat-
ment for breast cancer, which then prevents lymph fl  uid 
circulating into blood vessels and leads it to enter adja-
cent tissues and to raise oncotic pressure. Consequently, 
edema is developed due to the migration of water into 
tissues.
1
Treatment for lymphedema causes a reduction of ede-
ma by facilitating lymphatic circulation. Good reduction 
in lymphedema through treatment of lymphedema after 
breast cancer treatment has taken place has been report-
ed by several studies with wide reduction ranges from 
20% to 80%.
3-5 It appears that the degree of reduction may 
be diff  erent according to the method of assessing lymph-
edema and the difference of the time interval between 
pre-treatment and post-treatment measurement. In our 
study, it was also observed that the level of lymphedema 
was reduced after lymphedema treatments.
Diff  erent from the results for upper extremity function, 
in the survey assessing quality of life, M stage was shown 
to be a signifi  cant parameter aff  ecting quality of life. Th  e 
diff  erence of quality of life according to the presence or 
absence of breast cancer metastasis has been reported by 
several studies. In some studies, it has been stated that 
breast cancer metastasis is associated with depression 
and overall quality of life, and it has also been reported 
that the recurrence of breast cancer strongly lowered 
Table 4. Regression Coeffi   cients (p-value) for the EORTC-QLQ-Br23 Results
 
Functional scale Symptom scale
Body 
image
Sexual 
functioning
Sexual 
enjoyment
Future 
perspective
Systemic therapy 
side eff  ect
Breast 
symptoms
Arm 
symptoms
Upset by 
hair loss
Age NS -.025 (.026) -.039 (.011) NS NS NS NS NS
Side NS NS NS NS NS NS NS NS
Breast cancer stage
TN S N S N S N S N S N S N S N S
NN S N S N S N S N S N S N S N S
MN S N S N S N S N S N S N S N S
Stage NS NS NS NS NS NS NS NS
Breast cancer treatment
Postoperation 
period
NS NS NS NS NS NS NS NS
ALND NS NS NS NS NS NS NS NS
Radiotherapy NS NS -.660 (.043) NS NS NS NS NS
Chemotherapy NS NS NS NS NS NS NS NS
Hormone therapy NS NS NS .667 (.041) NS NS NS NS
Lymphedema 
duration (year)
NS NS NS NS NS NS NS NS
Self massage NS NS NS NS NS NS NS NS
NS: Not statistically signifi  cant (p>0.05), ALND: Axillary lymph node dissection
Table 5. Reduction of Arm Circumference after Lymph-
edema Treatment
Mean (cm) S.D. p-value
Metacarpophalangeal joint 0.11  0.55  0.32 
Wrist 0.30 0.91 0.00
10 cm below Elbow 0.66  1.04  0.00 
Elbow 0.53 0.80  0.00 
10 cm above Elbow 0.38  0.84  0.00 Ji Eung Park, et al.
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the quality of life of patients, and even their guardians.
6,7 
Th   is appears to be due to a fear of additional metastasis 
as well as the burden of additional treatments after me-
tastasis. In addition, it has been reported that the fear of 
recurrence becomes, in itself, a source of stress for pa-
tients.
8
It is well known that lymphedema treatments have a 
reduction effect on edema. Nevertheless, it has been 
claimed that a reduction in the size of the upper extremi-
ties in which edema has developed is associated neither 
with the quality of life nor with the upper extremities 
function, but rather the presence or absence of edema 
is more important than the size of edema.
2 In addition, 
it has been also reported that quality of life is not signifi  -
cantly associated with physical functions.
9-11 Th  e  satisfac-
tion level with treatments is a part of subjective evalua-
tion based on patients’ personal experiences, and quality 
of life is also a subjective construct that includes fi  nancial 
and the environmental factors as well as those related to 
treatment. In this study, the quality of life survey and the 
one relating to upper extremity function showed diff  erent 
distributions by category. Therefore, it can be proposed 
that when assessing the treatment of lymphedema, qual-
ity of life and upper extremity function should be evalu-
ated from diff  erent aspects.
One of the limitations of this study is that it was a cross-
section study which examined quality of life and the 
functional impairment of upper extremities in breast 
cancer related lymphedema patients, and thus informa-
tion about the cause-effect relationships or temporal 
sequences involved is necessarily limited. In addition, 
given that it was a retrospective study, additional pro-
spective and longitudinal studies on quality of life and 
upper extremity function in breast cancer related lymph-
edemapatients may be required. It is also necessary to 
develop treatments and programs that can improve of 
quality of life and upper extremity function in subjects, 
alongside a reduction in edema.
CONCLUSION
In terms of upper extremity function, it was found that 
older breast cancer related lymphedema patients had 
a lower level of upper extremity function than younger 
counterparts. Patients with metastasis had significantly 
lower quality of life scores on the physical and role func-
tioning subscales. Upper extremity function was not 
significantly associated with quality of life. In addition, 
it was found that the currently most-used lymphedema 
treatment was successful in reducing edema.
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Appendix 1. Study Questionnaire 
Name Age Weight Height Occupation
Underlying diseases Diabetes, Smoking, Kidney disease, Heart disease, Lung disease, Hypertension, 
Others (                          )
Lymphedema onset Lymphedema side Right, Left, Both
Chemotherapy history Yes, No Radiation therapy history Yes, No 
Lymphedema treatment Yes, No Dominant hand Right, Left
Massage
Self, Non-self
Yes, No
Self, Non-self
Check your conditions.
How often do you use your aff  ected arm?
                                                     Not at all                                                                                                        Very much
Do you have diffi   culty because of your lymphedema?
                                                     Not at all                                                                                                        Very much
Do you think that your lymphedema is well controlled?
                                                     Not at all                                                                                                        Very much
Do you satisfy your lymphedema treatment?
Yes (               )  No (               ) 
How much did your arm symptoms improve after 
lymphedema treatment?
Do you feel soft after lymphedema treatment?
(                       ) % Soft (    ) Stationary (    )